Multiple studies identified PD-L1 as a direct transcriptional target of YAP/TAZ/TEAD and showed that YAP and/or TAZ activation upregulates PD-L1 in human breast cancer, NSCLC, mesothelioma and melanoma cells [43]. The gene discussed is YAP1; the disease is breast carcinoma.